Elranatamab-bcmm Approved for Adult Patients With Relapsed or Refractory Multiple Myeloma
The novel drug elranatamab-bcmm (Elrexfio) received accelerated FDA approval on August 14, 2023, for treating adults with relapsed or refractory multiple myeloma.